ARTICLE | Deals
Chromatin remodeling gains traction with Merck-Foghorn partnership
Plus Merck, Zymeworks deal to develop multispecific antibodies
July 8, 2020 9:52 PM UTC
Merck’s Wednesday deal with Foghorn is the latest signal that chromatin remodeling is gaining traction.
Under the deal, Merck & Co. Inc. (NYSE:MRK) will have exclusive, global rights to cancer therapies targeting dysregulation of an undisclosed transcription factor that emerge from Foghorn Therapeutics Inc.’s chromatin structure-based Gene Traffic Control platform. Foghorn will receive $425 million via an undisclosed payment and milestones, plus royalties. ...